Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ortin GlobalBOM:539287 -0.99%41 Days Payable is 99.26 as of Mar. 2026, which is 6% above its 10-year median of 93.80. GuruFocus rates BOM:539287 with a GF Score™ of 41/100 and a GF Value™ of ₹2.52 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 925 Drug Manufacturers companies, Ortin Global ranks better than 79.57% on this metric.
The historical rank and industry rank for Ortin Global's Days Payable or its related term are showing as below:
BOM:539287'
s Days Payable Range Over the Past 10 Years
Min: 73.01 Med: 93.8 Max: 2833.92
Current: 170.33
During the past 13 years, Ortin Global's highest Days Payable was 2833.92. The lowest was 73.01. And the median was 93.80.
BOM:539287's Days Payable is ranked better than 79.57% of 925
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs BOM:539287: 170.33
Ortin Global's Days Payable
declined
from Mar. 2025 (433.69) to Mar. 2026 (99.26).
It may suggest that Ortin Globalaccelerated paying its suppliers.
Ortin Global Days Payable Related Terms
Ortin Global Days Payable Historical Data
* Premium members only.
The historical data trend for Ortin Global's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ortin Global's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ortin Global Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ortin Global's Days Payable distribution charts can be found below:
* The bar in red indicates where Ortin Global's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Ortin Global's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ortin Global (BOM:539287) has a Days Payable of 99.26 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ortin Global and its competitors. This is near median its historical median of 93.80. Over the past decade, Ortin Global's Days Payable has ranged from 73.01 to 2,833.92. According to the industry distribution chart, Ortin Global ranks #189 out of 925 companies in the Drug Manufacturers industry, placing it in the top 20.4%.
Is Ortin Global's Days Payable too high?
Ortin Global's current Days Payable of 99.26 is near median its 10-year median of 93.80. Over the past 10 years, this metric has ranged from a low of 73.01 to a high of 2,833.92. The Drug Manufacturers industry median Days Payable is 90.38. Ortin Global's value of 99.26 is 9.8% above this industry median. Based on the distribution chart, Ortin Global ranks #189 out of 925 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Ortin Global has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ortin Global's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ortin Global ranks #189 out of 925 companies for Days Payable. This places Ortin Global in the top 20% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.38. Ortin Global's value of 99.26 is 9.8% above this benchmark. Historically, Ortin Global's own Days Payable has ranged from 73.01 to 2,833.92 over the past decade. While the company's 10-year median is 93.80 vs. the industry median of 90.38, Ortin Global has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ortin Global's current Days Payable of 99.26 is 9.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ortin Global and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ortin Global's current Days Payable is 99.26, which is near median its own 10-year median of 93.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ortin Global stock overvalued right now?
Based on GuruFocus' analysis, Ortin Global (BOM:539287) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.52, compared to a current price of ₹15.00 — trading 495.2% above its estimated fair value. The current Days Payable is 99.26, which is near median its 10-year median of 93.80 and 9.8% above the Drug Manufacturers industry median of 90.38. Ortin Global's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Ortin Global (BOM:539287), the current Days Payable is 99.26 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ortin Global (BOM:539287) Overvalued in 2026?
Based on GuruFocus' analysis, Ortin Global stock appears to be overvalued.
The current stock price of ₹15.00 is trading 495.2% above its estimated GF Value™ of ₹2.52.
GuruFocus considers Ortin Global to be Significantly Overvalued.
Key valuation signals for BOM:539287:
Days Payable: 99.26 (near median its 10-year median of 93.80)
GF Value™: ₹2.52 vs. price of ₹15.00 (495.2% above fair value)
Industry Position: 9.8% above the Drug Manufacturers median (#189 of 925)
No single metric tells the full story. See the BOM:539287 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ortin Global Ltd is an Indian company engaged in the manufacturing and trading of Pharmaceuticals, Drugs, and Intermediates. Its formulations include anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helminthics, analgesics and antipyretics, antibiotics, antifungal, cephalosporins, and others. Some of its API intermediates include Ciprofloxacin, Tramadol, Efavarenz, Lamivudine, Zidovudine, Nevirapine, Lopinavir, Fluconazole, Triclabendazole, Omeprazole, and others. Additionally, the company is also involved in the real estate business.
41GF Score
Get the complete analysis for BOM:539287
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539287 has been successfully added to your 
